NCT07103395
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
Recruiting · Phase 2 · Sun Yat-sen University · registry updated 2026-01-14
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This study will enroll patients with locally advanced non-small cell lung cancer (NSCLC). Patients will receive neoadjuvant chemotherapy combined with dual immune checkpoint blockade (PD-1/CTLA-4), bevacizumab and thymosin alpha 1, followed by concurrent chemoradiotherapy, and finally consolidation therapy with dual immune checkpoint blockade (PD-1/CTLA-4), surufatinib and thymosin alpha 1. The study aims to evaluate the efficacy and safety of this treatment regimen.
Inclusion
- Males or females aged 18 to 75 years or older;
- Patients must have histologically or cytologically confirmed locally advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC);
- EGFR, ALK, and ROS1 wild-type;
- No prior chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy;
- Expected survival ≥ 12 weeks;
- WHO Performance Status (PS) score of 0 or 1;
Exclusion
- Exclusion criteria for enrolment for neoadjuvant therapy. Patients should not enter the study if any of the following exclusion criteria are fulfilled:
- Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study;
- Mixed small cell and non-small cell lung cancer histology;
- Prior use of anti-PD-1, anti-PD-L1, or anti-CTLA4 antibodies;
- Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access;
- Active or prior documented autoimmune disease within the past 2 years;